We are very pleased to demonstrate 20.7% weight loss and to see that 33% of patients achieved more than 25% weight loss with semaglutide 7.2 mg, with a safety and tolerability profile comparable to semaglutide 2.4 mg, said Martin Holst Lange, executive vice president for Development at Novo Nordisk
Appetite signaling, satiety, and gastrointestinal effects may be noticed earlier, but the outcomes people usually care about in the clinical literature, especially body-weight change, were measured over long study windows rather than days
Its like a slow-release energy bar for your cells
The study was supported by Novo Nordisk.
The company operates entirely online, handling consultations, prescriptions, and medication delivery through a single integrated system
You do not need to wait for the vial to reach full room temperature